KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and ...

An invasive tick species in Connecticut has been found to carry the bacteria that can cause ehrlichiosis in humans, a ...

Abeona Therapeutics' Zevaskyn, a cell therapy based on engineered keratinocytes harvested from patients, has been approved in the US as a treatment for the rare skin disorder recessive dystrophic ...

Rein Therapeutics ("Rein") , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, ...

Sickle cell disease (SCD) affects an estimated 20 ... are reshaping clinical trial methodologies, particularly in the rare disease space. By streamlining data collection, enhancing patient ...